Imaging Biomarkers or Biomarker Imaging?

Pharmaceuticals

Markus Mitterhauser¹ 

[1] Radiochemistry and Biomarker Development Unit, Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, A-1090 Vienna, Austria; E-Mail

关键词: tracer;    molecular probe;    PET;    radiopharmaceutical;   

DOI  :  10.3390/ph7070765

来源: mdpi

【 摘 要 】

Since biomarker imaging is traditionally understood as imaging of molecular probes, we highly recommend to avoid any confusion with the previously defined term “imaging biomarkers” and, therefore, only use “molecular probe imaging (MPI)” in that context. Molecular probes (MPs) comprise all kinds of molecules administered to an organism which inherently carry a signalling moiety. This review highlights the basic concepts and differences of molecular probe imaging using specific biomarkers. In particular, PET radiopharmaceuticals are discussed in more detail. Specific radiochemical and radiopharmacological aspects as well as some legal issues are presented.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.